Sökning: id:"swepub:oai:gup.ub.gu.se/164562" >
Analytical aspects ...
Analytical aspects of molecular Alzheimer's disease biomarkers
-
- Andreasson, Ulf, 1968 (författare)
- Gothenburg University,Göteborgs universitet,Institutionen för neurovetenskap och fysiologi, sektionen för psykiatri och neurokemi,Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry
-
Vanmechelen, E. (författare)
-
Shaw, L. M. (författare)
-
visa fler...
-
- Zetterberg, Henrik, 1973 (författare)
- Gothenburg University,Göteborgs universitet,Institutionen för neurovetenskap och fysiologi, sektionen för psykiatri och neurokemi,Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry
-
Vanderstichele, H. (författare)
-
visa färre...
-
(creator_code:org_t)
- Future Medicine Ltd, 2012
- 2012
- Engelska.
-
Ingår i: Biomarkers in Medicine. - : Future Medicine Ltd. - 1752-0363 .- 1752-0371. ; 6:4, s. 377-389
- Relaterad länk:
-
https://gup.ub.gu.se...
-
visa fler...
-
https://doi.org/10.2...
-
visa färre...
Abstract
Ämnesord
Stäng
- In general, a biomarker has multiple uses such as a diagnostic tool and a method to monitor therapy. The quality of a biomarker depends on how big the difference is between, for example, patients and healthy controls, but also on the capacity of the method used to measure it (the uncertainty in the method should be much less than the difference between the groups). A good biomarker should also be specific towards a disease, allowing for differentiation between clinically related syndromes. In addition, it is of importance that the stability of the methods used is high enough to establish cut-off levels both in individual laboratories and on a global scale. In the field of Alzheimer's disease, there are currently three cerebrospinal fluid markers that have been verified in multiple studies and the analytical aspects of measuring them will be discussed.
Ämnesord
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Neurologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Neurology (hsv//eng)
Nyckelord
- accuracy
- Alzheimer's disease
- biomarkers
- cerebrospinal fluid
- pathophysiology
- quality control
- amyloid-beta peptides
- cerebrospinal-fluid biomarkers
- mild cognitive
- impairment
- tandem mass-spectrometry
- phosphorylated tau
- quantitative-analysis
- csf biomarkers
- protein
- diagnosis
- beta-amyloid((1-42))
- baton m
- 1994
- biochemical and biophysical research communications
- v200
- p1598
Publikations- och innehållstyp
- ref (ämneskategori)
- for (ämneskategori)
Hitta via bibliotek
Till lärosätets databas